Search results for "Neuroprotective Agent"

showing 10 items of 156 documents

Dietary phytoestrogens improve stroke outcome after transient focal cerebral ischemia in rats.

2006

As phytoestrogens are postulated as being neuroprotectants, we assessed the hypothesis that dietary isoflavone-type phytoestrogens are neuroprotective against ischemic stroke. Transient focal cerebral ischemia (90 min) was induced by middle cerebral artery occlusion (MCAO) following the intraluminal thread technique, both in rats fed with soy-based diet and in rats fed with isoflavone-free diet. Cerebro-cortical laser-Doppler flow (cortical perfusion, CP), arterial blood pressure, core temperature, PaO2, PaCO2, pH and glycemia were measured before, during and after MCAO. Neurological examination and infarct volume measurements were carried out 3 days after the ischemic insult. Dietary isofl…

Malemedicine.medical_specialtyTime FactorsIschemiaNeurological examinationPhytoestrogensNeuroprotectionchemistry.chemical_compoundInternal medicineStroke outcomemedicineLaser-Doppler FlowmetryAnimalsRats WistarChromatography High Pressure LiquidNeurologic Examinationmedicine.diagnostic_testbusiness.industryGeneral NeuroscienceNeurological statusBody WeightCerebral InfarctionIsoflavonesmedicine.diseaseDietRatsStrokeDisease Models AnimalBlood pressureEndocrinologyNeuroprotective AgentschemistryIschemic Attack TransientAnesthesiaReperfusionPhytoestrogensbusinessThe European journal of neuroscience
researchProduct

Pravastatin treatment causes a shift in the balance of hippocampal neurotransmitter binding densities towards inhibition

2009

Since pravastatin, a HMG-CoA reductase inhibitor, has recently been shown to reduce infarct volumes and glutamate release in a rat model of ischemic stroke, the aim of the present study was to investigate whether this neuroprotective effect may be due to a modulation of excitatory and inhibitory neurotransmitter receptors. Therefore, Wistar rats were treated six times in 4 days with pravastatin or saline and allowed to survive for 6 hours or 5 days (n=10 per time point and group), respectively. Using quantitative receptor autoradiography, ligand binding densities of [(3)H]MK-801, [(3)H]AMPA, and [(3)H]muscimol for labeling of NMDA, AMPA, and GABA(A) receptors were analyzed in sensorimotor c…

Malemedicine.medical_specialtyTime FactorsKainate receptorAMPA receptorBiologyPharmacologyHippocampusReceptors N-Methyl-D-AspartateNeurotransmitter bindingRandom Allocationchemistry.chemical_compoundInternal medicinemedicineAnimalsReceptors AMPARats WistarLong-term depressionMolecular Biology5-HT receptorPravastatinCerebral CortexNeurotransmitter AgentsGABAA receptorGeneral NeuroscienceGlutamate receptorReceptors GABA-ACorpus StriatumRatsNeuroprotective AgentsEndocrinologynervous systemMuscimolchemistryNeurology (clinical)Developmental BiologyBrain Research
researchProduct

Early-onset tolerance in rat global cerebral ischemia induced by a mitochondrial inhibitor

2000

It was studied whether a subtoxic dose of the mitochondrial neurotoxin, 3-nitropropionic acid (3-NPA), can initiate early-onset tolerance induction for subsequent ischemic injury. Wistar rats were pretreated for 3 h by intraperitoneal 3-NPA (20 mg/kg body weight; n=13) or solvent (n=12). Fifteen minutes global cerebral ischemia was induced by bilateral carotid artery occlusion and hypobaric hypotension. rCBF and tissue hemoglobin oxygen saturation were measured by laser Doppler scanning and a microspectrophotometric method. Ischemic insult and brain temperature were identical in both groups. Body weight and neurological scores recovered in the pretreated group but further deteriorated in th…

Malemedicine.medical_specialtyTime FactorsNeurotoxinsIschemiaConvulsantsMotor ActivityHippocampal formationBrain IschemiaCentral nervous system diseaseBrain ischemiaProsencephalonInternal medicinemedicineAnimalsNeurotoxinRats WistarNeuronsNeocortexbusiness.industryGeneral NeuroscienceNitro Compoundsmedicine.diseaseMitochondriaRatsTolerance inductionNeuroprotective Agentsmedicine.anatomical_structureEndocrinologyReperfusion InjuryAnesthesiaPropionatesbusinessReperfusion injuryNeuroscience Letters
researchProduct

Pioglitazone Reduces Secondary Brain Damage after Experimental Brain Trauma by PPAR-γ-Independent Mechanisms

2011

Inflammatory and ischemic processes contribute to the development of secondary brain damage after mechanical brain injury. Recent data suggest that thiazolidinediones (TZDs), a class of drugs approved for the treatment of non-insulin-dependent diabetes mellitus, effectively reduces inflammation and brain lesion by stimulation of the peroxisome proliferator-activated receptor-γ (PPAR-γ). The present study investigates the influence of the TZD pioglitazone and rosiglitazone on inflammation and secondary brain damage after experimental traumatic brain injury (TBI). A controlled cortical impact (CCI) injury was induced in male C57BL/6 mice to investigate following endpoints: (1) mRNA expression…

Malemedicine.medical_specialtyTraumatic brain injuryPeroxisome proliferator-activated receptorInflammationStimulationBrain damageMiceDiabetes mellitusInternal medicinemedicineAnimalsHypoglycemic Agentschemistry.chemical_classificationPioglitazonebusiness.industrymedicine.diseaseMice Inbred C57BLPPAR gammaDisease Models AnimalNeuroprotective AgentsEndocrinologychemistryBrain InjuriesBrain Damage ChronicThiazolidinedionesNeurology (clinical)medicine.symptombusinessRosiglitazonePioglitazonemedicine.drugJournal of Neurotrauma
researchProduct

Amphiphilic polyaspartamide copolymer-based micelles for rivastigmine delivery to neuronal cells

2012

A novel polysorbate-80 (PS(80))-attached amphiphilic copolymer comprising a hydrophilic α,β-poly(N-2-hydroxyethyl)-D,L-aspartamide (PHEA) backbone and hydrophobic squalenyl-C(17) (Sq(17)) portions was synthesized and characterized; the formation of polymeric micelles was also evaluated. Rivastigmine free-base (Riv), a hydrophobic drug employed to treat Alzheimer's disease, was chosen as model drug to investigate micelle's ability to incorporate hydrophobic molecules and target them to neuronal cells. Micelle formation was studied through analyses including fluorescence spectroscopy and 2D (1)H-NMR NOESY experiments. Finally, the capacity of Riv-loaded micelles, versus free drug, to penetrat…

Materials sciencePhenylcarbamatesPharmaceutical ScienceRivastigminepolyaspartamide micelles rivastigmine drug delivery neuronal cellsMicelleFluorescence spectroscopyHydrophobic effectMiceNeuroblastomachemistry.chemical_compoundDrug Delivery SystemsCell Line TumorAmphiphileCopolymerAnimalsHumansOrganic chemistryParticle SizeMicellesAlkylNeuronschemistry.chemical_classificationPolysorbateDrug CarriersGeneral MedicineHydrophobeNeuroprotective AgentsSpectrometry FluorescencechemistryBiophysicsPeptidesHydrophobic and Hydrophilic InteractionsDrug Delivery
researchProduct

Inhalational or intravenous anesthetics for craniotomies? Pro inhalational.

2006

In neurosurgery, anesthesiologists and surgeons focus on the same target - the brain. The nature of anesthetics is to interact with brain physiology, leading to favorable and adverse effects. Research in neuroanesthesia over the last three decades has been dedicated to identifying the optimal anesthetic agent to maintain coupling between cerebral blood flow and metabolism, keep cerebrovascular autoregulation intact, and not increase cerebral blood volume and intracranial pressure.Sevoflurane is less vasoactive than halothane, enflurane, isoflurane, or desflurane. The context sensitive half-life is short and similar to that of desflurane, which translates into fast on and offset. Compared wi…

Methyl Ethersmedicine.medical_specialtyIntracranial PressureMEDLINESevofluraneCardiovascular Physiological PhenomenaSevofluraneMedicineHomeostasisHumansAdverse effectPropofolMonitoring PhysiologicEpilepsybusiness.industryPatient SelectionIntravenous AnestheticsBrainElectroencephalographyAnesthesiology and Pain MedicineNeuroprotective AgentsAnesthesiaCerebrovascular CirculationAnesthesia Recovery PeriodAnesthetics InhalationPostoperative Nausea and VomitingNeurosurgeryAnesthesia Recovery PeriodbusinessAnesthetics IntravenousCraniotomymedicine.drugCurrent opinion in anaesthesiology
researchProduct

Indicaxanthin, a multi-target natural compound from Opuntia ficus-indica fruit: From its poly-pharmacological effects to biochemical mechanisms and m…

2019

Abstract Over the latest years phytochemical consumption has been associated to a decreased risk of both the onset and the development of a number of pathological conditions. In this context indicaxanthin, a betalain pigment from Opuntia ficus-indica fruit, has been the object of sound research. Explored, at first, for its mere antioxidant potential, Indicaxanthin is now regarded as a redox-active compound able to exert significant poly-pharmacological effects against several targets in a number of experimental conditions both in vivo and in vitro. This paper aims to provide an overview on the therapeutical effects of indicaxanthin, ranging from the anti-inflammatory to the neuro-modulatory…

Models MolecularPyridinesOpuntia ficusPhytochemicalsContext (language use)Antioxidant potential01 natural sciencesMiceStructure-Activity Relationship03 medical and health scienceschemistry.chemical_compoundMulti targetCell Line TumorNeoplasmsSettore BIO/10 - BiochimicaBetalainDrug DiscoveryAnimalsHumansCell Proliferation030304 developmental biologyInflammationIndicaxanthin Multi-target compound Poly-pharmacology Antioxidant Antiinflammatory Antitumoral Antiproliferative Neuromodulator Molecular modellingPharmacologyBiological Products0303 health sciencesDose-Response Relationship DrugMolecular StructureTraditional medicine010405 organic chemistryNatural compoundOrganic ChemistryOpuntiaGeneral MedicineAntineoplastic Agents PhytogenicSettore CHIM/08 - Chimica FarmaceuticaBetaxanthins0104 chemical sciencesMice Inbred C57BLNeuroprotective AgentsPhytochemicalchemistryBlood-Brain BarrierFruitDrug Screening Assays AntitumorIndicaxanthinEuropean Journal of Medicinal Chemistry
researchProduct

Neuronal injury in chronic CNS inflammation.

2010

Introduction Multiple sclerosis (MS) is the most common chronic inflammatory disease of the central nervous system which is characterized by inflammatory demyelination and neurodegeneration. Neurological symptoms include sensory disturbances, optic neuritis, limb weakness, ataxia, bladder dysfunction, cognitive deficits and fatigue. Pathophysiology The inflammation process with MS is promoted by several inflammatory cytokines produced by the immune cells themselves and local resident cells like activated microglia. Consecutive damaging pathways involve the transmigration of activated B lymphocytes and plasma cells, which synthesize antibodies against the myelin sheath, boost the immune atta…

Multiple SclerosisInflammationNeuroprotectionSeverity of Illness IndexProinflammatory cytokineCentral Nervous System DiseasesmedicineAnimalsHumansRemyelinationNeuroinflammationInflammationNeuronsMicrogliabusiness.industryMultiple sclerosismedicine.diseaseAstrogliosisAnesthesiology and Pain Medicinemedicine.anatomical_structureNeuroprotective AgentsImmunologyChronic DiseaseMicrogliamedicine.symptomInflammation MediatorsbusinessBest practiceresearch. Clinical anaesthesiology
researchProduct

Neurodegeneration in multiple sclerosis: novel treatment strategies.

2012

In recent years it has become clear that the neuronal compartment already plays an important role early in the pathology of multiple sclerosis (MS). Neuronal injury in the course of chronic neuroinflammation is a key factor in determining long-term disability in patients. Viewing MS as both inflammatory and neurodegenerative has major implications for therapy, with CNS protection and repair needed in addition to controlling inflammation. Here, the authors' review recently elucidated molecular insights into inflammatory neuronal/axonal pathology in MS and discuss the resulting options regarding neuroprotective and regenerative treatment strategies.

Multiple SclerosisInflammationNeuroprotectionmedicineAnimalsHumansPharmacology (medical)In patientMolecular Targeted TherapyNeuroinflammationNeuronsEvidence-Based Medicinebusiness.industryGeneral NeuroscienceMultiple sclerosisNeurodegenerationAnti-Inflammatory Agents Non-SteroidalNeurodegenerative Diseasesmedicine.diseasePathology of multiple sclerosisNeuroprotective AgentsTreatment strategyEducation Medical ContinuingNeurology (clinical)medicine.symptombusinessNeuroscienceExpert review of neurotherapeutics
researchProduct

Beta-amyloid monomers are neuroprotective

2009

The 42-aa-long β-amyloid protein—Aβ1-42—is thought to play a central role in the pathogenesis of Alzheimer's disease (AD) (Walsh and Selkoe, 2007). Data from AD brain (Shankar et al., 2008), transgenic APP (amyloid precursor protein)-overexpressing mice (Lesné et al., 2006), and neuronal cultures treated with synthetic Aβ peptides (Lambert et al., 1998) indicate that self-association of Aβ1-42monomers into soluble oligomers is required for neurotoxicity. The function of monomeric Aβ1-42is unknown. The evidence that Aβ1-42is present in the brain and CSF of normal individuals suggests that the peptide is physiologically active (Shoji, 2002). Here we show that synthetic Aβ1-42monomers support …

N-MethylaspartateStimulationPeptideNeuroprotectionNeuro-degenerative diseasePathogenesismental disordersNitrilesmedicineAmyloid precursor proteinButadienesExcitatory Amino Acid AgonistsAnimalsEnzyme InhibitorsReceptorCells CulturedPodophyllotoxinchemistry.chemical_classificationCerebral CortexNeuronsAnalysis of VarianceAmyloid beta-PeptidesbiologyCell DeathDose-Response Relationship DrugGeneral NeuroscienceNeurodegenerationβ-Amyloid proteinNeurotoxicityself-assemblyTyrphostinsmedicine.diseaseEmbryo MammalianPeptide FragmentsCell biologyRatsNeuroprotective Agentschemistrybiology.proteinBrief CommunicationsNeuroscienceβ-Amyloid protein; Neuro-degenerative diseases; self-assembly
researchProduct